US · Healthcare · Biotechnology
EPS came in at -0.13 against a street estimate of -0.15 — a beat of 13.3%.
Analysts rate Sana Biotechnology Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $8.43.
| Fund | Stake |
|---|---|
| FMR Inc | 13.49% |
| Flagship Ventures Management, Inc. | 9.01% |
| RA Capital Management, LLC | 6.76% |
| BlackRock Inc | 6.01% |
| State Street Corp | 4.04% |
| Canada Pension Plan Investment Board | 3.68% |
| Vanguard Capital Management, LLC | 3.02% |
| Bank of America Corp | 2.07% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 SANA BIOTECHNOLOGY, INC. – 8-K FILING SUMMARY HEADLINE NUMBERS • No specific financial metrics, revenue figures, or operational results are disclosed | 2026-09-08 |
| Quarterly report · Q2 2026 SANA BIOTECHNOLOGY, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and marketable securities: $160.5 million as of June 30, 2026 ( | 2026-08-10 |
| Results announced · Q3 2026 SANA BIOTECHNOLOGY Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $160.5 million as of June 30, 2026, up $22.1 million from $13 | 2026-08-10 |
| Shareholder vote results · Q2 2026 SANA BIOTECHNOLOGY, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 4, 2026 • Total votes cast for director elections: ap | 2026-06-05 |
| Company announcement · Q2 2026 SANA BIOTECHNOLOGY, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company sold 21,607,878 shares of common stock on May 15, 2026 • Aggregate net proceeds fr | 2026-05-15 |
| Quarterly report · Q1 2026 SANA BIOTECHNOLOGY, INC. — 10-Q SUMMARY (Q1 2026) --- HEADLINE NUMBERS • Cash Position: $83.8 million in cash and equivalents + $17.3 million in ma | 2026-05-11 |
| Proxy statement · Q2 2026 SANA BIOTECHNOLOGY, INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Class II Directors – Vo | 2026-04-24 |
| Annual report FY2025 SANA BIOTECHNOLOGY, INC. — 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company: Sana Biotechnology, Inc. (Nasdaq: SANA) — cell enginee | 2026-03-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sana Biotechnology Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.